You are here: Industry Insights > M&A

News List

Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices fiercepharma
January 16, 2019
Biopharma experts predicting an M&A boom this year said one thing might thwart that surge of dealmaking: federal action on drug prices. If buyers can't charge what they want for the drugs they pick up in a merger, then the value of that deal could quickly
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......
Takeda’s Shire takeover could herald new era of pharma M&A pharmaphorum
January 10, 2019
Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma.
Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout fiercepharma
January 08, 2019
On the first day of biopharma’s largest confab, the J.P. Morgan Healthcare Conference, Eli Lilly confirmed that big-ticket M&A is back in fashion in the industry.
Verily pockets $1B with eyes on partnerships, M&A fiercebiotech
January 07, 2019
Six weeks after canning its Novartis-partnered glucose-sensing contact lens project, Verily is raising a $1 billion round that will power new partnerships, “global business development opportunities” and potential acquisitions.....
The top 10 medtech companies of 2024 fiercebiotech
January 03, 2019
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and ......
Bristol-Myers Squibb nears $1.6B sale of OTC unit Upsa to Taisho: report fiercepharma
January 03, 2019
Amid an industrywide shift away from the sector, Bristol-Myers Squibb is close to becoming the latest Big Pharma to exit consumer health. And word is Japan’s Taisho will be the one to help the company do it.
Clovis should put itself up for sale, activist Armistice says: report fiercepharma
December 26, 2018
Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target.
GSK, Pfizer go for radical makeovers with giant consumer combo destined for spinoff fiercepharma
December 25, 2018
Turns out, after GlaxoSmithKline walked away from a chance to scoop up Pfizer’s consumer health business in March, it got another opportunity to team up on a deal.
Will pharma's exodus from consumer health continue into 2019? It sure looks that way fiercepharma
December 24, 2018
The year 2018 might be remembered by the pharma world for a deluge of consumer health castoffs. And one doesn’t really need a crystal ball to see the trend continue into the near future as drugmakers turn

Previous page 1 2 3 4 5 6 Next page